Skip to main
  1. Stocks
  2. InflaRx
  3. Forecast
IFRX

InflaRx (IFRX) Stock Forecast & Price Target

InflaRx (IFRX) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

InflaRx is attractive because izicopan appears to combine a validated C5aR mechanism with a meaningfully better product profile than Tavneos, including faster pharmacology, no SAEs or TEAEs in more than 180 subjects, and simpler dosing. The opportunity is amplified by Tavneos’ commercial success, with $643M in 2025 worldwide AAV sales, alongside mounting regulatory and safety concerns, including FDA-cited 76 DILI cases and proposed withdrawal, which could open share for a safer alternative. Financially, the company ended 2Q26 with no debt and about €158M cash, and its pipeline also offers upside through renal indications and partnering optionality if izicopan’s upcoming studies continue to validate the thesis.

Bears say

InflaRx is a high-risk biopharma with weak current commercial traction, as GOHIBIC/vilobelimab has been effectively wound down in active U.S. commercialization and the company booked only about €29K of revenue against roughly €18.0M of SG&A expense in 2025, underscoring a severe mismatch between spend and sales. Its long-term value depends heavily on partnership-driven development and uncertain clinical expansion, while even promising opportunities such as AAV face entrenched approved competitors and a need for meaningful differentiation and commercial infrastructure that InflaRx lacks. The outlook is further pressured by expected losses for several years, likely additional capital needs, and unresolved legal and patent risks, any of which could dilute shareholders or limit the company’s ability to protect and monetize its pipeline.

InflaRx (IFRX) has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of InflaRx and is not a guaranteed prediction by Public.com or investment advice.

InflaRx (IFRX) Analyst Forecast & Price Prediction

Get the latest InflaRx (IFRX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in InflaRx (IFRX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About InflaRx (IFRX) Forecast

Analysts have given InflaRx (IFRX) a Buy based on their latest research and market trends.

According to 6 analysts, InflaRx (IFRX) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

InflaRx (IFRX)


InflaRx (IFRX) Analyst Forecast & Price Prediction

Get the latest InflaRx (IFRX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in InflaRx (IFRX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover IFRX stock data and trends